MedPath

Evaluation of Betaxolol in improving the acute phase of patients with mild to moderate Traumatic Brain Injury

Phase 3
Recruiting
Conditions
Traumatic Brain Injury.
Intracranial injury
Registration Number
IRCT20240415061488N1
Lead Sponsor
Bagheiat-allah University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
104
Inclusion Criteria

Patients with mild to moderate traumatic brain injury (GCS score of 9 or above)
Age 18 to 65 years old

Exclusion Criteria

Patients with penetrating head trauma
Unspecified time of trauma
Patients with spinal cord injury
Patients with cardiovascular diseases
Hemodynamic instability
Candidates for craniotomy

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Score of Glasgow Outcome Scale Extended (GOSE). Timepoint: Day 1 and 14 after taking medication. Method of measurement: Glasgow Outcome Scale Extended (GOSE) Questionnaire.
Secondary Outcome Measures
NameTimeMethod
Score of The Working Memory Questionnaire. Timepoint: Day 1 and 14 after taking medication. Method of measurement: The Working Memory Questionnaire.;Score of Visual analogue scale (VAS). Timepoint: Day 1 and 14 after taking medication. Method of measurement: Visual analogue scale (VAS).;Score of Mini Mental State Examination (MMSE). Timepoint: Day 1 and 14 after taking medication. Method of measurement: Score of Mini Mental State Examination (MMSE).;Presence of drug side effects. Timepoint: Day 1 and 14 after taking medication. Method of measurement: If the patient confirms any side effects of the drug Yes otherwise No.
© Copyright 2025. All Rights Reserved by MedPath